Fluoxetine for Bulimia Nervosa

Inspect the conclusion, its exact scope, the statements used to support it, and when each source was checked. This page does not add clinical advice or extend the published research beyond its stated scope.

Published assessment

Only this Treatment × Need pair is assessed here.

1 distinct published sources

Research suggests benefit in this exact scope

Published Sep 20, 2026 · revision 1

Reasoning and support

Open any source row to inspect scope and supporting text.

conclusion

The retained fluoxetine label reports three multicenter studies for bulimia nervosa; this assessment does not determine personal suitability or compare fluoxetine with every alternative.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: supports bounded conclusion

Scope: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter, parallel-group studies of adult outpatients meeting DSM-III-R criteria for bulimia.

Open source

Relationship source

Why this Treatment appears in the Need landscape, separate from the research conclusion.

DailyMed fluoxetine hydrochloride label · checked Sep 19, 2026

Relationship: label-reported clinical studies for the Need

Scope: country:US

Pointer: /sections/4

Supporting passage: The effectiveness of fluoxetine for the treatment of bulimia was demonstrated in two 8-week and one 16-week, multicenter, parallel-group studies of adult outpatients meeting DSM-III-R criteria for bulimia.

Open source

See something wrong? Tell us. Your note is private. We check sources before we change this page.